Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

1733.TW

STRONG BUYREMOVE

Apex Biotechnology Corp. · Healthcare · Taiwan · $93M · Avg Vol: $214K/d

91
StockRank
Q
70
V
67
M
47
P/E (TTM)
18.1x
ROE
10.2%
D/E
0.1x
Dividend %
4.4%
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

Apex Biotechnology manufactures blood glucose monitoring systems. It operates in a highly commoditized medical device niche with intense pricing pressure from global giants, failing our moat and pricing power criteria.

COMPANY DESCRIPTION

Apex Biotechnology Corp. designs, develops, and manufactures biosensors, primarily blood glucose monitoring systems and test strips. The company serves as an OEM/ODM partner for global medical device brands, supported by FDA and CE-certified manufacturing facilities. It is a niche medical technology player leveraging advanced electrochemical biosensor technology to capture steady recurring revenue from consumable test strips.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGR
Revenue—70.9M53.0M58.5M61.5M-4.7%
EPS0.060.060.040.04—-14.2%
Shares—100.0M100.0M100.0M100.0M+0.0%
Debt—7.7M5.7M5.3M4.7M-15.2%
Equity—57.4M56.8M57.6M59.1M1.0%
Op CF—0.8M7.3M10.4M5.1M81.9%
Inv CF—-1.3M-0.7M-1.1M-0.2M—
Fin CF—-7.5M-5.3M-4.7M-4.1M—
Loading...
PRICE (1Y)+2.8%
0.910.920.940.960.97May 14Jun 4Jun 25
SMA 50SMA 200
Close
$0.94
RSI (14)
52.6
52W High
$1.17
From 52W High
0.8%

SCORE BREAKDOWN

Quality
70
ROIC
9.7%72.8
ROE
10.2%72.1
GP/Assets
23.0%52.5
Op. Margin
16.8%77.8
FCF/Assets
6.0%74.9
Piotroski
782.3
Int. Cover
50.0x88.4
D/E Ratio
0.06x72.8
Current Ratio
3.14x55.4
Value
67
P/E (TTM)
18.1x61.9
EV/EBITDA
10.8x64.1
P/FCF
637.9x56.8
P/B
1.6x67.2
P/S
1.5x74.8
Div Yield
4.4%87.2
Momentum
47
52W High %
80%72.3
RS 6M
-64%15.2
SMA 50/200
0.96x51.6
EPS Rev 4W
+0.5%76.1
EPS Rev 12W
—N/A
EPS Improve
—31.9
Q Growth
31%69.3

FUNDAMENTALS

Market Cap
$93M
P/E (Forward)
15.4x
Gross Margin
28.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 1733.TW are excluded.

TickerCompanyMkt CapStockRankSignal
1733.TWApex Biotechnology Corp.(you)$93M91STRONG BUY
8279.TWOSyngen Biotech Co.,Ltd.$82M87STRONG BUY
1762.TWChunghwa Chemical Synthesis & Biotech Co., Ltd.$87M76BUY
1734.TWSinphar Pharmaceutical Co.,Ltd.$193M85STRONG BUY
4167.TWOSavior Lifetec Corporation$193M80STRONG BUY
1760.TWPanion & Bf Biotech Inc.$163M77BUY
4162.TWOPharmaEngine, Inc.$256M74BUY
4728.TWOSunmax Biotechnology Co., Ltd.$648M78BUY
6634.TWOSinew Pharma Inc.$143M35SELL
4130.TWOGenovate Biotechnology Co., Ltd.$109M29SELL

Peer medians: ROE 3.4% · P/E 16.0x · Gross margin 42.1%

Apex Biotechnology Corp. (1733.TW) — Stock Score Summary

Apex Biotechnology Corp. (1733.TW) has a MoatMap StockRank of 91/100 based on Quality (70/100), Value (67/100), and Momentum (47/100) factor scores. The current signal is STRONG BUY. Apex Biotechnology manufactures blood glucose monitoring systems. It operates in a highly commoditized medical device niche with intense pricing pressure from global giants, failing our moat and pricing power criteria.

Apex Biotechnology Corp. designs, develops, and manufactures biosensors, primarily blood glucose monitoring systems and test strips. The company serves as an OEM/ODM partner for global medical device brands, supported by FDA and CE-certified manufacturing facilities. It is a niche medical technology player leveraging advanced electrochemical biosensor technology to capture steady recurring revenue from consumable test strips.

Key Financial Metrics

Price$0.94
Market Cap$93M
P/E (TTM)18.12
P/E (Forward)15.37
Price/Book1.62
Return on Equity10.2%
Return on Invested Capital9.7%
Debt/Equity5.95
Gross Margin28.9%
Operating Margin16.8%
Revenue Growth-7.0%
Dividend Yield4.4%
Free Cash Flow$146K

Apex Biotechnology Corp. operates in the Biotechnology industry, part of the Healthcare sector (Taiwan).

Frequently Asked Questions

What is Apex Biotechnology Corp.’s (1733.TW) StockRank?
MoatMap’s StockRank for Apex Biotechnology Corp. (1733.TW) is 91/100, with a Strong Buy signal. It is a composite of Quality (70), Value (67), and Momentum (47) factor ranks across MoatMap’s 20,000+ stock universe.
Does Apex Biotechnology Corp. have an economic moat?
Apex Biotechnology Corp. (1733.TW) has a Quality factor score of 70/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Apex Biotechnology Corp. a buy, hold, or sell?
MoatMap’s current signal for Apex Biotechnology Corp. (1733.TW) is Strong Buy, based on a StockRank of 91/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Apex Biotechnology Corp. in?
Apex Biotechnology Corp. (1733.TW) operates in the Healthcare sector, specifically the Biotechnology industry (Taiwan).
Browse all ranked stocks1733.TW deep dive reportAI ChampionsHow we score stocksSense-check another stock